You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Emerging Treatments for Diabetic Macular Edema: New Data

  • Authors: Arshad M. Khanani, MD, MA; Dante J. Pieramici, MD; Charles C. Wykoff, MD, PhD
  • CME Released: 4/2/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 4/2/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for ophthalmologists and diabetologists/endocrinologists.

The goal of this activity is to disseminate the latest clinical data on emerging agents with novel mechanisms of action for the treatment of diabetic macular edema (DME).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of angiopoietin-2 in retinal diseases
    • Mechanism of action of emerging DME therapies
    • Latest clinical data on emerging DME therapies


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Arshad M. Khanani, MD, MA

    Clinical Associate Professor
    University of Nevada
    Managing Partner
    Director of Clinical Research
    Director of Fellowship
    Sierra Eye Associates
    Reno, Nevada

    Disclosures

    Disclosure: Arshad M. Khanani, MD, MA, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adverum; Allergan; Bausch and Lomb; Chengdu Kanghong Biotechnologies; DORC; Eyepoint Pharmaceuticals; Genentech; Gyroscope; Gemini Therapeutics; IVERIC Bio; Kodiak Sciences; Novartis; Opthea; Oxurion; Recens Medical; Regenx Bio
    Served as a speaker or a member of a speakers bureau for: Allergan; Genentech; Novartis
    Received grants for clinical research from: Adverum; Allergan; Changdu Kanghong Biotechnologies; Genentech; Gemini Therapeutics; Gyroscope; IVERIC Bio; Kodiak Sciences; Novartis; Opthea, Oxurion; Recens Medical; RegenX Bio; Roche

  • Dante J. Pieramici, MD

    Vitreoretinal Surgeon
    California Retinal Consultants
    Director, California Retina Research Foundation
    Santa Barbara, California

    Disclosures

    Disclosure: Dante J. Pieramici, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adverum; Gemini Therapeutics; Genentech; Regeneron; RegenX Bio
    Received grants for clinical research from: Apellis; Gemini Therapeutics; Genentech; Graybug Vision; Gyroscope; Kodiak Sciences; NGM Biopharmaceuticals; Novartis; Regeneron; Stealth

  • Charles C. Wykoff, MD, PhD

    Associate Professor of Clinical Ophthalmology
    Weill Cornell Medical College
    Director of Research, Retina Consultants of Houston
    Deputy Chair of Ophthalmology
    Blanton Eye Institute and Houston Methodist Hospital
    Houston, Texas

    Disclosures

    Disclosure: Charles C. Wykoff, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adverum; Allergan; Apellis; Arctic Vision; Arrowhead; Bausch and Lomb; Bayer; Bionic Vision Technologies; Chengdu Kanghong Biotechnologies; EyePoint; Genentech; Gyroscope; IVERIC Bio; Kato DSRC; Kodiak Sciences; Merck; NGM Biopharmaceuticals; Novartis; OccuRx; Ocular Therapeutix; ONL Therapeutics; Opthea; Oxurion [formerly Thrombogenics]; Palatin; Pentavision; PolyPhotonix; Recens Medical; Regeneron; RegenXBio; Roche; SAI MedPartners; Takeda; Thea Open Innovation; Verana Health
    Received grants for clinical research from: Adverum; Aerie Pharmaceuticals; Aldeyra; Alimera Sciences; Apellis; Bayer; Boehringer Ingelheim; Chengdu Kanghong Biotechnologies; Clearside Biomedical; Gemini Therapeutics; Genentech; Graybug Vision; Gyroscope; IONIS Pharmaceutical; IVERIC Bio; Kodiak Sciences; LMRI; Neurotech Pharmaceuticals; NGM Biopharmaceuticals; Novartis; Opthea; Outlook Therapeutics; Oxurion; Recens Medical; Regeneron; RegenX Bio; Roche; SamChunDang Pharm.; Santen; Senju; Taiwan Liposome Company; Xbrane BioPharma

Editor

  • Pakinam Aboulsaoud, PharmD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

The PIM planners and others have nothing to disclose.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alimera; Allergan; Carl Zeiss Meditec; Thea.


Accreditation Statements

Developed through a partnership between Medscape and Postgraduate Institute for Medicine (PIM)



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medscape, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    For Optometrists


    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medscape. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Postgraduate Institute for Medicine is accredited by COPE to provide continuing education to optometrists.

    Credit Statement: This course is COPE approved for 0.75 hours of CE credit. Activity #121461 and Course ID 72020-PS. Check with your local state licensing board to see if this counts toward your CE requirement for re-licensure.

    Reviewed by

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Emerging Treatments for Diabetic Macular Edema: New Data

Authors: Arshad M. Khanani, MD, MA; Dante J. Pieramici, MD; Charles C. Wykoff, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 4/2/2021

Valid for credit through: 4/2/2022

processing....

Educational Impact Challenge

The goal of this activity is to disseminate the latest clinical data on emerging agents with novel mechanisms of action for the treatment of diabetic macular edema.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print